Evidence map›Paper›PMID 37061631›Full record

ArticleCancer immunology, immunotherapy : CII2023

Engineered murine IL-21-secreting leukemia cells induce granzyme B

Alexandra Berger, Sarah J Colpitts, Morgan Zych, Christopher J Paige

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8Journal of gastroenterology and hepatology · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Alexandra BergerPrincess Margaret Cancer Centre, University Health Network, Room 8-105, Toronto, ON, M5G 2M9, Canada. aberger@uhnres.utoronto.ca.
Sarah J ColpittsPrincess Margaret Cancer Centre, University Health Network, Room 8-105, Toronto, ON, M5G 2M9, Canada.
Morgan ZychPrincess Margaret Cancer Centre, University Health Network, Room 8-105, Toronto, ON, M5G 2M9, Canada.
Christopher J PaigePrincess Margaret Cancer Centre, University Health Network, Room 8-105, Toronto, ON, M5G 2M9, Canada.
University Health Network · CAPrincess Margaret Cancer Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have explored the use of an IL-21 cell-based anti-leukemia treatment in a mouse model of acute lymphoblastic leukemia. 70Z/3 leukemia cells, engineered to secrete IL-21 and injected into the peritoneum of syngeneic mice, induced a strong anti-leukemia response resulting in 100% survival. Mice that mounted an IL-21-induced anti-leukemia immune response were immune to the parent cell line (no IL-21) when rechallenged.Above a certain threshold, IL-21 secretion correlated with improved survival compared to mice injected with parent 70Z/3 cells. IL-21 was detected in serum with peak levels on day 7, correlating with the maximum expansion of IL-21-secreting 70Z/3 cells which subsequently were eliminated. Mice injected with IL-21-secreting leukemia cells had elevated numbers of granzyme B

Indexed as

LeukemiaNeoplasmsAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesGranzymesInterleukin-21MiceMice, Inbred C57BLT-Lymphocytes, RegulatoryGranzymesInterleukin-21Cancer immunotherapyInterleukin-21LeukemiaRegulatory T cellsT cells

Identifiers

PMID37061631
PMCPMC10991896
OpenAlexW4365813711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.